- Chimeric Therapeutics has strengthened its Cellular Immunotherapy Scientific Advisory Board with three highly regarded cell therapy experts.
- In August, the Company onboarded Dr Yi Lin as the first member of the advisory board.
- The team is expected to guide Chimeric with the latest scientific research as well as clinical perspectives.
Chimeric Therapeutics Limited (ASX:CHM) recently introduced a new Cellular Immunotherapy Scientific Advisory Board (CI-SAB) to gain expert guidance on the development of its growing pipeline of cellular immunotherapies. The Company plans to beef up its advisory board with world-class experts who have been part of successful development of several cellular immunotherapies.
Strengthening its CI-SAB team, Chimeric recently appointed three highly regarded cell therapy experts - Dr Eric Smith, Dr David G Maloney, and Dr Michael R Bishop.
The new additions follow the onboarding of Dr Yi Lin in August as the inaugural member of the advisory board.
DETAILED DISCUSSION AT: Chimeric onboards Dr Yi Lin to Cellular Immunotherapy Scientific Advisory Board
Meet Dr Eric Smith
Dr Smith specialises in cellular immunotherapy and haematological cancers with a focus on multiple myeloma, a type of blood cancer.
Currently, Dr Smith is-
- Director of Translational Research, Immune Effector Cell Therapies.
- Head of the Eric Smith Lab for Synthetic Biology and Cellular Engineering at the Dana-Farber Cancer Institute.
- Member of the Faculty of Medicine at Harvard Medical School in Boston, Massachusetts.
Dr Smith deploys modern advances in gene engineering and cellular manipulation for designing as well as screening novel cell therapy strategies in order to advance them to clinic.
Meet Dr David G Maloney
Dr Maloney is a well-known clinician-scientist who has been at the forefront of cellular therapy research & development with a primary focus on the development of CAR (chimeric antigen receptor) T cell therapy.
Meet Dr Michael R Bishop
Dr Bishop is a pioneer and widely recognised expert in cell therapy research and patient care, with a focus on leukaemia and lymphomas. He has served as an investigator for multiple clinical trials examining novel cellular immunotherapies, including Phase 1 clinical trials for autologous and allogeneic CAR T and TCR (T Cell Receptor Engineering) products.
Currently, Dr Bishop is working as a Professor of Medicine and Director at the University of Chicago.
Welcoming the new appointments, Jennifer Chow, CEO and Managing Director of Chimeric, said:
“We are honoured to have these outstanding individuals joining our scientific advisory board. They bring deep translational expertise in cellular therapy development and are each very respected visionaries and contributors to the field. As we move into our next phase of growth we expect the insights and guidance they will bring to the table to be of great value to Chimeric.”
Chimeric Therapeutics is focused on advancing its oncology product pipeline with innovative cell therapy assets that will bring the promise of cellular therapy to life for more patients suffering from challenging cancers.
The scientific advisory board is expected to ensure the growth and development of the Company, guiding Chimeric with the latest scientific research as well as clinical perspectives.
CHM shares traded at AU$0.0.315 on 20 September 2021.